Literature DB >> 3167364

The significance of depression in the prediction of relapse in chronic schizophrenia.

D A Johnson1.   

Abstract

The prospective monitoring of two separate groups of chronically schizophrenic patients on regular depot maintenance therapy suggests that depression developing after an interval of 1 year from recovery from an acute relapse indicates a significant increase in the risk of a further relapse within 2 years, compared with depression within the first year, or no depression. Patients with such depression were more prone to relapses than other patients, despite regular medication within normal dose ranges. The results suggest that the aetiology of depression occurring in patients after 1 year in a stable mental state is different from that of depression within the first year, and in many patients, the former represents underlying schizophrenic activity prior to an early relapse.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3167364     DOI: 10.1192/bjp.152.3.320

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  12 in total

Review 1.  Pharmacological treatment of patients with schizophrenia. Past and present problems and potential future therapy.

Authors:  D A Johnson
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

2.  Association between depression in chronic phase and future clinical outcome of patients with schizophrenia.

Authors:  Yuto Yamada; Yusuke Yamauchi; Shinji Sakamoto; Masaki Fujiwara; Yuko Okahisa; Soshi Takao; Manabu Takaki; Norihito Yamada
Journal:  Psychopharmacology (Berl)       Date:  2022-02-21       Impact factor: 4.530

3.  Reducing emergency medical service use in patients with chronic psychotic disorders: results from the FAST intervention study.

Authors:  Brent T Mausbach; Veronica Cardenas; Christine L McKibbin; Dilip V Jeste; Thomas L Patterson
Journal:  Behav Res Ther       Date:  2007-10-07

4.  Specificity of emotion-related effects on attentional processing in schizotypy.

Authors:  Aprajita Mohanty; Wendy Heller; Nancy S Koven; Joscelyn E Fisher; John D Herrington; Gregory A Miller
Journal:  Schizophr Res       Date:  2008-04-28       Impact factor: 4.939

Review 5.  The use of carbamazepine in the treatment of schizophrenic and schizoaffective psychoses: a review.

Authors:  C Simhandl; K Meszaros
Journal:  J Psychiatry Neurosci       Date:  1992-03       Impact factor: 6.186

Review 6.  Psychiatric comorbidities and schizophrenia.

Authors:  Peter F Buckley; Brian J Miller; Douglas S Lehrer; David J Castle
Journal:  Schizophr Bull       Date:  2008-11-14       Impact factor: 9.306

7.  A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: Results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone.

Authors:  Delbert G Robinson; Juan A Gallego; Majnu John; Lauren A Hanna; Jian-Ping Zhang; Michael L Birnbaum; Jessica Greenberg; Melissa Naraine; Bart D Peters; Robert K McNamara; Anil K Malhotra; Philip R Szeszko
Journal:  Schizophr Res       Date:  2018-09-19       Impact factor: 4.939

8.  Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial.

Authors:  Eirik Kjelby; Hugo A Jørgensen; Rune A Kroken; Else-Marie Løberg; Erik Johnsen
Journal:  BMC Psychiatry       Date:  2011-08-31       Impact factor: 3.630

9.  Severity of psychotic episodes in predicting concurrent depressive and anxiety features in acute phase schizophrenia.

Authors:  Kalai Naidu; Werdie C W van Staden; Mike van der Linde
Journal:  BMC Psychiatry       Date:  2014-06-05       Impact factor: 3.630

10.  A review of quetiapine in combination with antidepressant therapy in patients with depression.

Authors:  Ella J Daly; Madhukar H Trivedi
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.